Severiano E Sousa Catarina, Alarcão Joana, Pavão Martins Isabel, Ferreira Joaquim J
Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz 1649-028, Lisbon, Portugal; Instituto de Medicina Molecular João Lobo Antunes, Av. Prof. Egas Moniz 1649-028, Lisbon, Portugal.
Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz 1649-028, Lisbon, Portugal; Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz 1649-028, Lisbon, Portugal.
J Neurol Sci. 2022 Jan 15;432:120077. doi: 10.1016/j.jns.2021.120077. Epub 2021 Dec 3.
There is a considerable variation in the reported frequency of dementia in Parkinson's disease (PDD). The aim of this study was to evaluate the frequency of PDD reported in published studies and to examine the different methodological, clinical, and demographic factors that may contribute to this variation.
We conducted a systematic review, searching EMBASE and MEDLINE databases for relevant articles on PDD frequency published before May 2019. A global estimation of PDD was calculated. Different subgroup analyses were performed for methodological, clinical, and demographic characteristics. Meta-regression was also conducted to identify any significant differences within the subgroups.
We included 295 studies. The global pooled dementia frequency was 26.3%. These estimations varied according to methodological (14%-55%), clinical (18%-46%), and demographic (21%-43%) variables. The declared primary objective of the studies (to study PDD), the follow-up length (≥7 years), the age of the participants (≥75 years), Parkinson's disease (PD) duration (>10 years), and the Hoehn & Yahr (H&Y) stage (>3) were important factors affecting reported dementia frequency.
This systematic review found that approximately one-quarter of the PD patients were diagnosed with PDD. Dementia frequency varied according to methodological, clinical and demographic variables. We cannot examine PDD frequency without considering all these variables that have an impact on it.
帕金森病（PDD）中痴呆症的报告发病率存在相当大的差异。本研究的目的是评估已发表研究中报告的PDD发病率，并研究可能导致这种差异的不同方法学、临床和人口统计学因素。
我们进行了一项系统评价，在EMBASE和MEDLINE数据库中检索2019年5月之前发表的关于PDD发病率的相关文章。计算了PDD的总体估计值。对方法学、临床和人口统计学特征进行了不同的亚组分析。还进行了Meta回归以确定亚组内的任何显著差异。
我们纳入了295项研究。总体合并痴呆症发病率为26.3%。这些估计值根据方法学（14%-55%）、临床（18%-46%）和人口统计学（21%-43%）变量而有所不同。研究声明的主要目的（研究PDD）、随访时间长度（≥7年）、参与者年龄（≥75岁）、帕金森病（PD）病程（>10年）和Hoehn&Yahr（H&Y）分期（>3期）是影响报告痴呆症发病率的重要因素。
这项系统评价发现，约四分之一的PD患者被诊断为PDD。痴呆症发病率根据方法学、临床和人口统计学变量而有所不同。如果不考虑所有这些对其有影响的变量，我们就无法研究PDD发病率。
